[Neuronal intranuclear inclusion disease (NIID)].
Adolescent
Adult
Age of Onset
Biopsy
Brain
/ diagnostic imaging
Diagnosis, Differential
Diffusion Magnetic Resonance Imaging
Female
Genetic Testing
Humans
Intranuclear Inclusion Bodies
/ genetics
Leukoencephalopathies
Male
Muscle Weakness
Neurodegenerative Diseases
/ diagnosis
Receptor, Notch2
/ genetics
Skin
/ pathology
Trinucleotide Repeats
Young Adult
DWI
NOTCH2NLC
intranuclear inclusion
leukoencephalopathy
skin biopsy
Journal
Rinsho shinkeigaku = Clinical neurology
ISSN: 1882-0654
Titre abrégé: Rinsho Shinkeigaku
Pays: Japan
ID NLM: 0417466
Informations de publication
Date de publication:
24 Oct 2020
24 Oct 2020
Historique:
pubmed:
8
9
2020
medline:
24
11
2020
entrez:
7
9
2020
Statut:
ppublish
Résumé
Neuronal intranuclear inclusion disease (NIID) is a progressive neurodegenerative disease that had been diagnosed by autopsy until recently, but the number of cases has increased since skin biopsy was reported to be useful in 2011. In 2019, the genetical cause of NIID was identified as the extension of the GGC repeat sequence on the NOTCH2NLC gene, and genetic diagnosis became possible. In NIID, there are two groups: a group onset with cognitive dysfunction, and with leukoencephalopathy on head MRI and a high intensity signal at the corticomedurally junction on DWI, and a group with limb weakness. It is necessary to include NIID in the differential diagnosis of leukoencephalopathy and neuropathy, and it is necessary to combine skin biopsy and genetic testing to accurately diagnose of NIID and promote pathological elucidation.
Identifiants
pubmed: 32893241
doi: 10.5692/clinicalneurol.cn-001417
doi:
Substances chimiques
NOTCH2 protein, human
0
Receptor, Notch2
0
Types de publication
Journal Article
Review
Langues
jpn
Sous-ensembles de citation
IM